Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
July 16, 2021 08:00 ET
|
Celularity, Inc.
Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021 Clinical pipeline includes multiple clinical...
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership
July 07, 2021 09:26 ET
|
Celularity, Inc.
FLORHAM PARK, N.J. & LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company leading the next evolution in cellular medicine with...
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
July 01, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J. and NAPLES, Fla., July 01, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company developing innovative cell therapies and biomaterial...
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia
June 29, 2021 08:25 ET
|
Celularity, Inc.
No dose limiting toxicity to date with outpatient administration of three doses (Days 0, 7 and 14) at total dose levels of 1.8, 3.6, and 5.4 Billion CYNK-001 cells, respectively Achievement...
Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer
May 20, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of...
Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies
May 05, 2021 08:00 ET
|
Celularity, Inc.
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes...
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
April 13, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
April 09, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., April 09, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
March 18, 2021 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
Celularity to Present at H.C. Wainwright Global Life Sciences Conference
March 09, 2021 11:21 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company focused on the development of innovative allogeneic placenta-derived...